Decoy Therapeutics Inc. — Operating Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c10e7fd5-080e-476a-bd55-8f67a418bb9e/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-12.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-134897 |
| FY 2024 | $-5.7M | 2024-01-01 – 2024-12-31 | evidence 0001615219-25-000037 |
| FY 2023 | $-12.9M | 2023-01-01 – 2023-12-31 | evidence 0001615219-24-000025 |
| FY 2022 | $-31.8M | 2022-01-01 – 2022-12-31 | evidence 0001615219-23-000030 |
| FY 2021 | $-12.8M | 2021-01-01 – 2021-12-31 | evidence 0001615219-22-000028 |
| FY 2020 | $-7.8M | 2020-01-01 – 2020-12-31 | evidence 0001615219-21-000026 |
| FY 2019 | $-8.3M | 2019-01-01 – 2019-12-31 | evidence 0001615219-20-000014 |
| FY 2018 | $-1.7M | 2018-01-01 – 2018-12-31 | evidence 0001615219-20-000014 |
| FY 2017 | $-34.7M | 2017-01-01 – 2017-12-31 | evidence 0001615219-18-000018 |
| FY 2016 | $-39.9M | 2016-01-01 – 2016-12-31 | evidence 0001615219-17-000021 |
| FY 2015 | $-29.2M | 2015-01-01 – 2015-12-31 | evidence 0001615219-17-000021 |
| FY 2014 | $-8.0M | 2014-02-26 – 2014-12-31 | evidence 0001615219-17-000021 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).